Miyoshi Shion, Takasaki Jin, Mine Sohtaro, Kono Masanori, Igari Toru, Takeda Yuichiro, Hojo Masayuki, Sugiyama Haruhito
Department of Pulmonary Medicine, National Center for Global Health and Medicine, Japan.
Department of Respiratory Medicine, Toho University Omori Medical Center, Japan.
Intern Med. 2017;56(9):1079-1083. doi: 10.2169/internalmedicine.56.7944. Epub 2017 May 1.
Anti-tumor necrosis factor α (anti-TNFα) agents increase the risk of tuberculosis (TB), but cases are rarely fatal. This report concerns a patient who was undergoing treatment with infliximab and presented with acute respiratory distress syndrome due to miliary TB without a miliary shadow. The findings of a pathological autopsy revealed innumerable granulomas in the organs, and the miliary nodules in the lung consisted of more unstructured granulomas. Anti-TNFα agents are unusual in the presentation of TB. It is important, particularly for patients receiving anti-TNFα agents, to constantly consider the possibility of TB and to prepare for appropriate management.
抗肿瘤坏死因子α(抗TNFα)药物会增加患结核病(TB)的风险,但病例很少致命。本报告涉及一名正在接受英夫利昔单抗治疗的患者,该患者因粟粒性肺结核出现急性呼吸窘迫综合征,但无粟粒影。病理尸检结果显示器官中有无数肉芽肿,肺部的粟粒结节由更多结构松散的肉芽肿组成。抗TNFα药物在结核病表现方面不常见。对于接受抗TNFα药物治疗的患者来说,持续考虑患结核病的可能性并做好适当管理的准备非常重要。